Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J7KR
|
|||
| Drug Name |
Lenalidomide
|
|||
| Synonyms |
Lenalidomide; Revlimid; Revimid; CC-5013; Lenalidomide (CC-5013); CDC 501; CC 5013; CDC-501; NCGC00167491-01; AK-47482
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 3 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H13N3O3
|
|||
| Canonical SMILES |
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
|
|||
| InChI |
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
|
|||
| InChIKey |
GOTYRUGSSMKFNF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 191732-72-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:63791
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial (GETAFE) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.